During the last session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares were 0.34 million, with the beta value of the company hitting 0.34. The 52-week high for the BCLI share is $1.08, that puts it down -350.0 from that peak though still a striking 45.83% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $19.36M, and the average intraday trading volume over the past 10 days was 0.29 million shares, and the average trade volume was 450.30K shares over the past three months.
Brainstorm Cell Therapeutics, Inc. (BCLI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. BCLI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Brainstorm Cell Therapeutics, Inc. (BCLI) registered a 1.17% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.17% in intraday trading to $0.24, hitting a weekly high. The stock’s 5-day price performance is -13.90%, and it has moved by -32.78% in 30 days. Based on these gigs, the overall price performance for the year is -76.20%. The short interest in Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is 1.29 million shares and it means that shorts have 2.63 day(s) to cover.
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Statistics show that Brainstorm Cell Therapeutics, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Brainstorm Cell Therapeutics, Inc. (BCLI) shares have gone down -49.42% during the last six months, with a year-to-date growth rate more than the industry average at 62.75% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 78.60% this quarter and then jump 88.90% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.57%. While earnings are projected to return 62.50% in 2024.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. is due to release its next quarterly earnings on 2024-Nov-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s Major holders
Brainstorm Cell Therapeutics, Inc. insiders own 8.99% of total outstanding shares while institutional holders control 15.42%, with the float percentage being 16.94%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 54.0 institutions own stock in it. As of 2024-06-30, the company held over 7.92 million shares (or 12.2302% of all shares), a total value of $2.68 million in shares.
The next largest institutional holding, with 1.51 million shares, is of VANGUARD GROUP INC’s that is approximately 2.3334% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.51 million.
